SETH MILLER: Open Payments
NPI 1346521945 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,840 in 183 payments from 18 companies in 2025. Trend: 2023 $3,372 · 2024 $3,458 · 2025 $3,840
Food & beverage: $3,789Education: $51
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 58 | $1,169 |
| Janssen Biotech, Inc. | 32 | $708 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 20 | $320 |
| GENZYME CORPORATION | 9 | $251 |
| Ipsen Biopharmaceuticals, Inc | 5 | $237 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $235 |
| Madrigal Pharmaceuticals | 5 | $210 |
| PFIZER INC. | 13 | $181 |
| Lilly USA, LLC | 6 | $106 |
| Phathom Pharmaceuticals, Inc. | 6 | $99 |
Products named: TREMFYA, SKYRIZI, XIFAXAN, RINVOQ, DUPIXENT, IQIRVO, LINZESS, REZDIFFRA.
Industry payments across LA — which companies pay providers there.
